[11C]Sorafenib: Radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer

Nuclear Medicine and Biology

Volumn 40, Issue 4, 2013, Pages 488-497

  Poot, Alex J ^a   van der Wildt, Berend ^a   Stigter van Walsum, Marijke ^a   Rongen, Marissa ^a   Schuit, Robert C ^a   Hendrikse, N Harry ^a   Eriksson, Jonas ^a   van Dongen, Guus A M S ^a   Windhorst, Albert D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carbon 11; Personalized medicine; Sorafenib; TKI PET; Tyrosine kinase inhibitor

Indexed keywords

CARBON 11; FLUORODEOXYGLUCOSE F 18; METHYL GROUP; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; SORAFENIB C 11; TRACER; UNCLASSIFIED DRUG; UREA; CARBANILAMIDE DERIVATIVE; CARBON; CD31 ANTIGEN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG PURITY; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; CHEMISTRY; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES; RADIOCHEMISTRY; RAT; SCINTISCANNING; TUMOR CELL LINE; DRUG ANTAGONISM; METHODOLOGY;

ANIMALS; ANTIGENS, CD31; CARBON RADIOISOTOPES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; MALE; MICE; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RAF; RADIOACTIVE TRACERS; RADIOCHEMISTRY; RATS;

EID: 84876711882     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.02.002     Document Type: Article

References (30)

1. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
2. Johnson L.N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009, 1:1-40.
3. Ou S.-H.I. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. CRC Cr Rev Oncol Hem 2012, 83:407-421.
4. Van Dongen G.A.M.S., Poot A.J., Vugts D.J. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumor Biol 2012, 3:607-615.
5. Slobbe P., Poot A.J., Van Dongen G.A.M.S., Windhorst A.D. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. Drug Disc Today 2012, 17:1175-1187.
6. Tolmachev V., Stone-Elander S., Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010, 11:992-1000.
7. Kil K.E., Ding Y.-S., Lin K.-S., Alexoff D., Kim S.W., Shea C., et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 2007, 34:153-163.
8. 11C]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. J Lab Compd Radiopharm 2006, 49:883-888.
9. 11C]Iressa: radiosynthesis, in vitro uptake, and in vivo imaging of intact fibrosarcoma. Mol Imaging Biol 2010, 12:181-191.
10. 18F]-Iressa and related molecular probes. J Label Compd Radiopharm 2005, 48:829-843.
11. 18F]-gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008, 35:1089-1099.
12. 18F] SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett 2005, 15:4380-4383.
13. 11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009, 69:873-878.
14. 18F-lapatinib: a potential tracer for positron emission tomography imaging of Erb1/Erb2 tyrosine kinase activity. J Label Compd Radiopharm 2011, 54:633-636.
15. 11C]Sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. Bioorg Med Chem Lett 2011, 21:2220-2223.
16. Weber B., Winterdahl M., Memon A., Sorensen B.S., Keiding S., Sorensen L., et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011, 6:1287-1289.
17. Memon A.A., Weber B., Winterdahl M., Jakobsen S., Meldgaard P., Madsen H.H., et al. PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer 2011, 105:1850-1855.
18. Bahce I., Lubberink M., Smit E., Windhorst A.D., Yaqub M., Lammertsma A.A., et al. A potential clinical PET tool for quantitative imaging of activating EGFR mutations in non small cell lung carcinoma. J Nucl Med Meeting Abstracts 2011, 52:600.
19. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006 Oct, 5:835-844.
20. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
21. Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006, 12:7271-7278.
22. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
23. 11C]carbon monoxide. Org Biomol Chem 2004, 2:3063-3066.
24. 11C]methyl iodide. Appl Radiat Isot 1987, 38:601-603.
25. Bayer Corporation. 2003, Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors. U.S. Patent, 2003144278.
26. 11C]ureas via triphenylphosphinimines. J Label Compd Radiopharm 2006, 49:321-330.
27. 11C]CO carbonylation and first evaluation as a P-gp tracer in rats. EJNMMI Res 2012, 2:36.
28. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
29. Agarwal S., Sane R., Ohlfest J.R., Elmquist W.F. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 2011, 336:223-233.
30. Lagas J.S., van Waterschoot R.A., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010, 9:319-326.